Royalty Pharma (RPRX) Profit After Tax (2019 - 2026)

Royalty Pharma has disclosed Profit After Tax across 8 years of filings, most recently posting $294.7 million for Q1 2026.

• Profit After Tax for Q1 2026 came in at $294.7 million, down 32.17% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.0 billion (down 41.52% YoY), and the FY2025 annual result was $1.3 billion, changed 0.5% from the prior year.
• Profit After Tax came in at $294.7 million for Q1 2026 at Royalty Pharma, down from $355.9 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of $806.4 million in Q3 2024 to a low of -$456.1 million in Q4 2022.
• The 5-year median for Profit After Tax is $288.2 million (2025), against an average of $249.2 million.
• Across the five-year window, Profit After Tax sank 172.47% in 2022 and surged 8992.36% in 2025, its largest moves.
• Royalty Pharma's Profit After Tax stood at -$456.1 million in 2022, then soared by 208.39% to $494.3 million in 2023, then sank by 32.36% to $334.4 million in 2024, then increased by 6.45% to $355.9 million in 2025, then declined by 17.2% to $294.7 million in 2026.
• The last three Profit After Tax figures came in at $294.7 million (Q1 2026), $355.9 million (Q4 2025), and $288.2 million (Q3 2025), per Business Quant data.